Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.
1. A solid dispersion comprising amorphous N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide.
2. The solid dispersion of claim 1 , further comprising a surfactant, polymer, or inert pharmaceutically acceptable substance.
3. The solid dispersion of claim 1 , further comprising a polymer.
4. The solid dispersion of claim 3 , wherein the polymer is hydroxypropylmethylcellulose acetate succinate (HPMCAS).
5. The solid dispersion of claim 3 , wherein the polymer is present in an amount of from about 10% by weight to about 80% by weight.
6. The solid dispersion of claim 5 , wherein the polymer is present in an amount of less than about 70% by weight.
7. The solid dispersion of claim 1 , wherein the N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide is present in an amount of from about 10% by weight to about 80% by weight.
8. The solid dispersion of claim 1 , further comprising a surfactant.
9. The solid dispersion of claim 8 , wherein the surfactant is sodium lauryl sulfate.
10. The solid dispersion of claim 8 , wherein the surfactant is present in an amount from about 0.1 to about 5%.
11. The solid dispersion of claim 10 , wherein the surfactant is present in 0.5%.
12. The solid dispersion according to claim 1 , wherein the solid dispersion is obtained by spray drying.
13. A pharmaceutical composition comprising amorphous N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide as a solid dispersion.
14. The pharmaceutical composition of claim 13 , further comprising a polymer.
15. The pharmaceutical composition of claim 14 , wherein the polymer is hydroxypropylmethylcellulose (HPMC) or hydroxypropylmethylcellulose acetate succinate (HPMCAS).
16. The solid dispersion of claim 3 , wherein the polymer is at least one water-soluble or partially water-soluble polymer.
17. The pharmaceutical composition of claim 14 , wherein the polymer is at least one water-soluble or partially water-soluble polymer.
18. A pharmaceutical composition comprising amorphous N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide as a solid dispersion and a polymer.
19. The pharmaceutical composition of claim 18 , wherein the polymer is at least one water-soluble or partially water-soluble polymer.
20. The pharmaceutical composition of claim 18 , wherein the polymer is hydroxypropylmethylcellulose acetate succinate (HPMCAS).
21. A solid dispersion comprising N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, hydroxypropylmethylcellulose acetate succinate (HPMCAS) and sodium lauryl sulfate.
22. A pharmaceutical composition comprising the solid dispersion of claim 21 .